Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 201–300 of 793
Fraz, M. A., Warraich, F. H., Warraich, S. U., Tariq, M. J., Warraich, Z., Khan, A. Y., Usman, M., Ijaz, A., Tenneti, P., Mushtaq, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.011 · Cited by 34
Management of Newly Diagnosed Elderly Multiple Myeloma Patients
Antoine-Pepeljugoski, C., & Braunstein, M. J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0804-4 · Cited by 37
Merz, M., Dechow, T. N., Scheytt, M., Schmidt, C., Hackanson, B., & Knop, S. T. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04023-4 · Cited by 29
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 32
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 31
Bladé, J., Rosiñol, L., & de Larrea, C. F. (2015) · Blood · doi:10.1182/blood-2014-10-551531 · Cited by 31
“The novel drugs thalidomide, bortezomib and lenalidomide have been associated with MP (MPT, MPV and MPR) or with low-dose dexamethasone (Rd) resulting in a superior PFS in almost all studies and in a significant OS prolongation in some of them (10-14).”
BackgroundManagement of multiple myeloma in older adults: Gaining ground with geriatric assessment
Wildes, T. M., & Campagnaro, E. L. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.04.001 · Cited by 31
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 33
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 33
“Ven-Vd: N=6 Ven-Kd: N=2 Ven-Dara-Vd: N=1 NA 6 (2-19) - 78%/NA/NA 6-mo PFS rate: 28%6-mo OS rate: 77% - Blood transfusion due to hematologic toxicities 40%”
BackgroundInfluentialFixed duration vs continuous therapy in multiple myeloma
Ludwig, H., & Zojer, N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.212 · Cited by 32
Self-citationBlommestein, H. M., van Beurden-Tan, C. H. Y., Franken, M. G., Groot, C. A. U., Sonneveld, P., & Zweegman, S. (2019) · Haematologica · doi:10.3324/haematol.2018.206912 · Cited by 37
“Figure 2 Network of the included studies in the network meta-analysis Legend: White boxes represent treatments and reference numbers using the following abbreviations; [1] Dexamethasone (D) [2] Dexamethasone-Interferon alpha (DI) [3] Melphalan 100 (M100) [4] Melphalan-Dexamethasone (MD) [5] Melphalan-Prednisone (MP) […”
Chromosomal instability and acquired drug resistance in multiple myeloma
Wang, W., Zhang, Y., Chen, R., Tian, Z., Zhai, Y., Janz, S., Gu, C., & Yang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20829 · Cited by 35
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0495-9 · Cited by 29
Hungria, V., Lee, J. H., Maiolino, Â., Crusoé, E. D. Q., Martınez, G., Bittencourt, R., Duarte, G. O., Fantl, D. B. E., Navarro, J. R., Conte, G. F., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03602-4 · Cited by 32
Self-citationNielsen, L. K., Stege, C. A. M., Lissenberg-Witte, B. I., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222299 · Cited by 32
“The FIRST trial compared continuous therapy with lenalidomide and dexamethasone (Rd), with Rd for 18 months, and melphalan-prednisone-thalidomide (MPT) for 18 months.(14) Clinically relevant changes were published only for six HRQoL scales.”
MethodMöller, M., Gengenbach, L., Graziani, G., Greil, C., Wäsch, R., & Engelhardt, M. M. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000792 · Cited by 29
Ferla, V., Antonini, E., Perini, T., Farina, F., Masottini, S., Malato, S., Marktel, S., Stanghellini, M. T. L., Tresoldi, C., Ciceri, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932852 · Cited by 36
“Similar questions exist also for the non-transplant-eligible patients, where the positive impact of continuous treatment on OS is not well demonstrated (71, 73, 74).”
BackgroundMoore, K. L. F., Turesson, I., Genell, A., Klausen, T. W., Knut‐Bojanowska, D., Redder, L., Sverrisdottir, I. S., Thorsen, J., Vangsted, A. J., & Blimark, C. H. (2022) · Haematologica · doi:10.3324/haematol.2021.280424 · Cited by 35
“3) Age in years, median (range) 65 (30-74) 80 (75-98) 66 (19-74) 81 (75-100)”
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
Ludwig, H., Rauch, E., Kuehr, T., Adam, Z., Weißmann, A., Kasparu, H., Autzinger, E.-M., Heintel, D., Greil, R., Poenisch, W., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.115204 · Cited by 30
Self-citationKikuchi, J., Kuroda, Y., Koyama, D., Osada, N., Izumi, T., Yasui, H., Kawase, T., Ichinohe, T., & Furukawa, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2446 · Cited by 30
The Investigational Proteasome Inhibitor Ixazomib for the Treatment of Multiple Myeloma
Richardson, P. G. G., Moreau, P., Laubach, J. P., Gupta, N., Hui, A.-M., Anderson, K. C., Miguel, J. F. S., & Kumar, S. K. (2015) · Future Oncology · doi:10.2217/fon.15.9 · Cited by 33
Self-citationMateos, M., Oriol, A., Martínez‐López, J., Teruel, A. I., Bengoechea, E., Palomera, L., de Arriba, F., Esseltine, D.-L. W., Cakana, A., Pei, L., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2835-3 · Cited by 30
“The results also bear similarities to those of the FIRST trial, which showed that continuous therapy (with lenalidomide– dexamethasone) can achieve superior PFS outcomes compared with fixed duration treatment in transplant-ineligible patients with MM [16].”
ResultSelf-citationPuig, N., Hernández, M. T., Rosiñol, L., González, E., de Arriba, F., Oriol, A., González‐Calle, V., Escalante, F., de la Rubia, J., Gironella, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00490-8 · Cited by 28
“R-ISS I includes ISS stage I, no high-risk CA [del(17p) and/or t(4;14) and/or t(14;16)], and normal LDH level (less than the upper limit of normal range); R-ISS III including ISS stage III and high-risk CA or high LDH level; and R-ISS II, including all other possible combinations.”
BackgroundSelf-citationLeBlanc, R., Bergstrom, D. J., Côté, J. A., Kotb, R. R., Louzada, M., & Sutherland, H. J. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.028 · Cited by 31
Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2021) · Cancers · doi:10.3390/cancers13184666 · Cited by 34
Usmani, S. Z., Cavenagh, J. D., Belch, A. R., Hulin, C., Basu, S., White, D. J., Nooka, A. K., Ervin-Haynes, A. L., Yiu, W., Nagarwala, Y. M., et al. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1115407 · Cited by 29
Self-citationHungria, V., Crusoé, E., Maiolino, Â., Bittencourt, R., Fantl, D. B. E., Maciel, J. F. R., Magalhães, R., Almeida, M. S. S., Cury, P., Hisgashi, F., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2537-2 · Cited by 28
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 31
“0168), as compared to therapy with melphalan, prednisone, and thalidomide (MPT) in the phase III FIRST trial [35].”
Self-citationTriplet vs. doublet drug regimens for managing multiple myeloma
Offidani, M., Corvatta, L., & Gentili, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1418856 · Cited by 28
“based on the results of the FIRST trial [34], enrolling 1623 patients who were randomly assigned to receive Rd continuously, Rd for”
MethodAvet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 27
“For patients with high-risk cytogenetic abnormalities, Rd continuous resulted in a numerically higher ORR than both MPT and Rd18 (77 vs 68 vs 67%, respectively), but did not demonstrate a significant improvement in PFS or OS vs MPT [19].”
BackgroundMethodInfluentialSelf-citationQuach, H., Fernyhough, L. J., Henderson, R. A., Corbett, G., Baker, B., Browett, P., Blacklock, H. A., Forsyth, C. J., Underhill, C. R., Cannell, P., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14562 · Cited by 27
Self-citationSequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000109 · Cited by 27
Mohyuddin, G. R., Koehn, K., Shune, L. O., Aziz, M., Abdallah, A.-O. A., McClune, B. L., Ganguly, S., McGuirk, J. P., & Kambhampati, S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1867725 · Cited by 33
“[22,25,26] and found a higher risk of death in patients with RI (n1⁄4 676) compared to those without RI (n1⁄4 1361), RR 1.”
BackgroundSurvival of ethnic and racial minority patients with multiple myeloma treated with newer medications
Pulte, D. D., Nie, L., Gormley, N. J., Goldberg, K. B., McKee, A., Farrell, A. T., & Pazdur, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017010512 · Cited by 29
Conticello, C., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Sapienza, G., Leotta, V., Parisi, M. S., Markovic, U., Garibaldi, B., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060877 · Cited by 29
“These observations are topical since several studies have indicated a clinical benefit of a maintenance therapy with lenalidomide in both transplant eligible [24,25] and non-transplant eligible patients [26], either for a fixed duration (18 months) or given continuously as shown by the FIRST trial [27].”
BackgroundZweegman, S., Stege, C. A. M., Haukås, E., Schjesvold, F. H., Levin, M., Waage, A., Leys, R. B. L., Klein, S. K., Szatkowski, D., Axelsson, P., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.240374 · Cited by 28
Lenalidomide is safe and active in W aldenström macroglobulinemia
Fouquet, G., Guidez, S., Petillon, M., Louni, C., Ohyba, B., Dib, M., Poulain, S., Herbaux, C., Martin, A., Thielemans, B., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24175 · Cited by 26
“Overall, the safety profile of lenalidomide in this WM population is similar to what was observed in MM elderly patients [3].”
BackgroundResultInfluentialSelf-citationGarderet, L., D’Souza, A., Jacobs, P., van Biezen, A., Schönland, S. O., Kröger, N. M., Morris, C., & Hari, P. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.03.009 · Cited by 30
“More recently, the combination of lenalidomide plus dexamethasone, given on an extended basis, was found to be superior to MP and thalidomide and represents a new standard of care for this patient population [28].”
BackgroundImmunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 29
Self-citationBortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma
Jimenez-Zepeda, V. H., Duggan, P. R., Neri, P. E., Tay, J., & Bahlis, N. J. (2017) · Annals of Hematology · doi:10.1007/s00277-016-2901-x · Cited by 27
Self-citationMechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 30
Scott, G. B., Carter, C. R. D., Parrish, C., Wood, P. M. D., & Cook, G. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.05.002 · Cited by 26
“Lenalidomide has been clearly demonstrated to have a significant anti-tumour effect in the clinical setting, mediated in part by cereblon-directed proteasomal degradation of Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3) [39,40], though the mechanism of action in the maintenance setting is not clear.”
BackgroundCurrent Treatment for Multiple Myeloma
Avigan, D., & Rosenblatt, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1407442 · Cited by 26
Mateos, M., Oriol, A., Rosiñol, L., de Arriba, F., Puig, N., Martín, J., Martínez‐López, J., Echeveste, M. A., Sarrá, J., Ocio, E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124818 · Cited by 32
“haematologica | 2015; 100(8) Plasma Cell Disorders”
InfluentialSelf-citationCurrent therapeutic strategies for multiple myeloma
Torimoto, Y., Shindo, M., Ikuta, K., & Kohgo, Y. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0826-3 · Cited by 27
“Continuous Rd as described above might be an option depending on the condition of the patient [53].”
BackgroundMethodMaes, H., & Delforge, M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1021772 · Cited by 26
“In contrast, in an analysis of the MM-020 trial (Rd, for 18 cycles or continuous till PD, vs MPT) that evaluated outcomes based on age (£75 years vs >75 years), continuous Rd increased PFS and had an acceptable overall tolerability compared to MPT, regardless of age [55,56].”
MethodSelf-citationChari, A., Parikh, K., Ni, Q., & Abouzaid, S. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.06.007 · Cited by 26
Managing multiple myeloma in elderly patients
Diamond, E., Lahoud, O. B., & Landau, H. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1365859 · Cited by 27
Rosenberg, A. S., Brunson, A. M., Tuscano, J. M., Jonas, B. A., Hoeg, R. T., Wun, T., & Keegan, T. H. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00400-4 · Cited by 26
Voorhees, P. M., Suman, V. J., Tuchman, S. A., Laubach, J. P., Hassoun, H., Efebera, Y. A., Mulkey, F. A., Bova‐Solem, M., Santo, K., Carlisle, D., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26361 · Cited by 28
McCaughan, G. J. B., Gandolfi, S., Moore, J. J., & Richardson, P. G. G. (2022) · British Journal of Haematology · doi:10.1111/bjh.18295 · Cited by 29
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
McCurdy, A. B. R., Mian, H. S., LeBlanc, R., Jimenez-Zepeda, V. H., Su, J., Masih‐Khan, E., Visram, A., Louzada, M., Song, K., White, D. J., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00883-x · Cited by 27
Self-citationRifkin, R. M., Abonour, R., Shah, J. J., Mehta, J., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Lu, J. J., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1132419 · Cited by 24
“0%, respectively.[9] Finally, a meta-analysis of seven clinical trials between 2000 and 2012 (which included MM-015) found invasive SPM in 3% of treated patients (105/ 3218).”
BackgroundSelf-citationTan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 26
Self-citationClinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas, S., Pukrop, T., Hackl, C., Herr, W., Ghibelli, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01357 · Cited by 24
“, 2010; Iland and Seymour, 2013) but both drugs are commonly administered combined with transcriptional modulators, alltrans-retinoic acid and dexamethasone, respectively (Lo-Coco et al., 2013; Benboubker et al., 2014).”
BackgroundNewly Diagnosed Myeloma in 2020
Moreau, P., Touzeau, C., Vij, R., Goldsmith, S. R., & Rosko, A. E. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280221 · Cited by 27
Self-citationManier, S., Lambert, J., Hulin, C., Macro, M., Laribi, K., Araujo, C., Pica, G. M., Touzeau, C., Godmer, P., Slama, B., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00280-3 · Cited by 33
Self-citationLarocca, A., & Palumbo, A. P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6113 · Cited by 25
“Recently, continuous lenalidomide and low-dose dexamethasone (Rd) was shown to be superior to MPT.(9)”
InfluentialBridoux, F., Chen, N., Moreau, S., Arnulf, B., Moumas, É., Abraham, J., Desport, É., Jaccard, A., & Fermand, J. P. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3068-9 · Cited by 27
“Lenalidomide combined with dexamethasone is indicated for the treatment of MM [8, 9], with an overall response rate (ORR) of about 60 % in patients with relapsed/refractory MM (RRMM) [10–12] and 75 % in those with newly diagnosed MM [13].”
BackgroundSelf-citationRaje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Self-citationOekelen, O. V., Amatangelo, M. D., Guo, M., Upadhyaya, B., Cribbs, A. P., Kelly, G., Patel, M., Kim‐Schulze, S., Flynt, E., Laganà, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101584 · Cited by 27
Lee, C., Grigorian, M., Nolan, R., Binder, G., & Rice, G. K. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2015.1130710 · Cited by 23
Treat or palliate: outcomes of very elderly myeloma patients
Panitsas, F. P., Kothari, J., Vallance, G. D., Djebbari, F., Ferguson, L., Sultanova, M., & Ramasamy, K. (2017) · Haematologica · doi:10.3324/haematol.2017.173617 · Cited by 24
Kastritis, E., Ρούσσου, Μ., Gavriatopoulou, M., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., Ziogas, D. C., Fotiou, D., Ntanasis‐Stathopoulos, I., Dialoupi, I., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000539 · Cited by 24
Self-citationThe Paraprotein - an Enduring Biomarker.
Tate, J. R. (2019) · Europe PMC (PubMed Central) · Cited by 47
Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy
Ramakrishna, R., DIAMOND, T. H., Alexander, W., Manoharan, A., & Golombick, T. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2735 · Cited by 24
Treatment of Patients with Newly-Diagnosed Multiple Myeloma
Bolaman, A. Z., & Turgutkaya, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105774 · Cited by 21
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis
Wang, X., Li, Y., & Yan, X. (2016) · BioMed Research International · doi:10.1155/2016/6848902 · Cited by 26
Current and Novel Alkylators in Multiple Myeloma
Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 26
“However, MPT proved inferior to the more convenient alkylator-free combination of lenalidomide and dexamethasone (Ld) [25] and, today, it is not used when other options are available.”
BackgroundSelf-citationGiannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 30
Taniwaki, M., Yoshida, M., Matsumoto, Y., Shimura, K., Kuroda, J., & Kaneko, H. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.014 · Cited by 21
Wildes, T. M., & Anderson, K. C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.88 · Cited by 24
Self-citationChallenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00500-4 · Cited by 24
Myeloma: management of the newly diagnosed high-risk patient
Dispenzieri, A. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.485 · Cited by 21
Self-citationGupta, N., Yang, H., Hanley, M. J., Zhang, S., Liu, R., Kumar, S. K., Richardson, P. G. G., Skácel, T., & Venkatakrishnan, K. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0524-3 · Cited by 24
“Furthermore, due to overlapping toxicities with lenalidomide, such as thrombocytopenia, gastrointestinal toxicities, and rash [4, 13, 14, 18, 22], higher doses of ixazomib would be expected to adversely affect the lenalidomide RDI.”
BackgroundNew developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Richardson, P. G. G., Kumar, S. K., Laubach, J. P., Paba‐Prada, C. E., Gupta, N., Berg, D. T., de Velde, H. J. V., & Moreau, P. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s102328 · Cited by 21
Self-citationNadiminti, K. V. G., Sidiqi, M. H., Meleveedu, K. S., Alkhateeb, H. B., Hogan, W. J., Litzow, M. R., Patnaik, M. M., Kumar, S. K., Gertz, M. A., Chen, D., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00454-y · Cited by 21
Role of ARK5 in cancer and other diseases (Review)
Mo, G., Zhang, B., & Jiang, Q. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10129 · Cited by 21
Lecat, C. S. Y., Taube, J. B., Wilson, W., Carmichael, J., Parrish, C., Wallis, G., Kyriakou, C. A., Lee, L. S. H., Mahmood, S., Papanikolaou, X. D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703233 · Cited by 23
Raje, N. S., Mateos, M., Iida, S., & Reece, D. E. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00804-y · Cited by 26
“In TI patients, standard treatments include lenalidomidebortezomib-dexamethasone or lenalidomide-daratumumabdexamethasone for fit patients and lenalidomide–low-dose dexamethasone for unfit patients (Table 1) [2, 6, 9, 27, 28].”
BackgroundGonsalves, W. I., Godby, K. N., Kumar, S. K., & Costa, L. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24129 · Cited by 22
“Palumbo et al, 2006[117] MP 164 72 NA 15% MPT 167 72 NA 13% Rajkumar et al, 2006[77] TD 99 65 28% 18% D 100 65 40% 20% Facon et al, 2007[118] MP 196 65–75 30% 21% MPT 125 65–75 29% 13% VAD-Mel100 126 65–75 35% 24% Rajkumar et al, 2008[100] TD 235 64 (mean) NA 18% D 235 64(mean) NA 22% San Miguel et al, 2008[8] VMP 344…”
Biran, N., Jacobus, S. J., Vesole, D. H., Callander, N. S., Fonseca, R., Williams, M. E., Abonour, R., Katz, M. S., Rajkumar, S. V., Greipp, P. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.68 · Cited by 23
Gentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Petrucci, M. T., Gay, F., Larocca, A., Uccello, G., Petrungaro, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24621 · Cited by 21
“2017;92: 244–250 dexamethasone (Rd) as first line therapy for elderly MM patients.11–13 Based on the results of one of these trials (FIRST MM-020)11 the American Food and Drug Administration and the European Medicines Agency (EMA) have expanded the existing indication for lenalidomide in combination with dexamethasone…”
BackgroundResultBahlis, N. J., Corso, A., Mügge, L.-O., Shen, Z.-X., Desjardins, P., Stoppa, A.-M., Decaux, O., de Revel, T., Granell, M., Marit, G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.111 · Cited by 23
Self-citationKatodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 23
Kantarjian, H. M., Prat, F., Steensma, D. P., Kurzrock, R., Stewart, D. J., Sekeres, M. A., & Leveque, J. A. (2018) · Cancer · doi:10.1002/cncr.31522 · Cited by 20
Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era
Chen, L., Fan, F., Deng, J., Xu, J., Xu, A., Sun, C., & Hu, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-018-3582-4 · Cited by 20
The pharmacologic management of multiple myeloma in older adults
Dempsey, J. L., Johns, A. C., Rosko, A. E., & Lazarus, H. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1577822 · Cited by 20
Russo, C. D., Cappoli, N., & Navarra, P. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02895-z · Cited by 20
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
Chen, T., Fallah, M., Brenner, H., Jansen, L., Mai, E. K., Castro, F. A., Katalinic, A., Emrich, K., Holleczek, B., Geiss, K., et al. (2016) · Scientific Reports · doi:10.1038/srep22084 · Cited by 20
A real‐world data analysis of predictors of early mortality after a diagnosis of multiple myeloma
Grant, S. J., Wildes, T. M., Rosko, A. E., Silberstein, J., & Giri, S. (2023) · Cancer · doi:10.1002/cncr.34760 · Cited by 26
“, poor PS(7,12,15,19,26,30,32) and reduced mobility(12)), (3) disease‐specific and laboratory characteristics (ISS stages II and III,(7,11,12,26,28,30,33) renal impairment,(7,12,14,28,31,32) elevated β2‐microglobulin levels,(4,13,15,19) elevated LDH,(7,11,13,15,16,33) hypercalcemia,(16,26,30) hypoalbuminemia,(4,13,15,…”
BackgroundMethodKiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U. G., de Vries, E. G. E., Ghia, P., Gökbuget, N., González‐Calle, V., Huntly, B. J. P., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000611 · Cited by 24
Specialty pharmacy for hematologic malignancies
Fajardo, S., Zook, F., & Dotson, E. K. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150749 · Cited by 20
Giri, S., Aryal, M. R., Yu, H., Grimshaw, A. A., Pathak, R., Huntington, S. P., & Dhakal, B. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.05.013 · Cited by 20
“b) CTD arm in Hungria et al(26) and that studied by Morgan et al(27) were considered identical regimens, since the cumulative dosing of thalidomide, cyclophosphamide and dexamethasone were similar and c) In Magarotto et al(28), all patients received indefinite lenalidomide maintenance; hence the RD arm was considered…”
MethodJackson, G. H., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Wilson, J. N., Taylor, C., Kishore, B., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16945 · Cited by 20
Mian, H. S., Seow, H. Y., Wildes, T. M., Kouroukis, C. T., Pond, G. R., Sivapathasundaram, B., & SUSSMAN, J. S. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.10.009 · Cited by 20
Ko, Y. H., Niedźwiecka, K., Casal, M., Pedersen, P. L., & Ułaszewski, S. (2018) · Yeast · doi:10.1002/yea.3367 · Cited by 19
“Drugs used in the treatment of MM cause accumulation of toxicity in organisms and consequently numerous side effects (Benboubker et al., 2014).”
BackgroundBoyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 19
“In a clinical trial involving elderly patients with previously untreated MM, continuous Rd was superior to fixed duration Rd and to melphalan, prednisolone, and thalidomide (MPT) [13].”
BackgroundSelf-citationChen, Y., Lairson, D. R., Chan, W., Huo, J. S., & Du, X. L. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.8.831 · Cited by 20
Liu, S., Shi, J., Guo, H., Xu, F., Wei, M., Sun, K., & Chen, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s227671 · Cited by 18
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.